WTO appears close to rejecting a proposed waiver on patents for Covid diagnostics and therapies; Years after a polarizing approval, Biogen walks away from Aduhelm

Taking stock of the drug industry, from the lab to the medicine chest

January 31, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | WTO appears close to rejecting a proposed waiver on patents for Covid diagnostics and therapies The effort began in June 2022, after the WTO reached a five-year arrangement to waive patent rights for Covid-19 vaccines. By Ed Silverman STAT+ | Years after a polarizing approval, Biogen walks away from Aduhelm Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. By Damian Garde STAT+ | Experts critique flawed system for monitoring drugs' side effects in wake of asthma drug report The FDA's Adverse Event Reporting System needs modernization, experts say, with links to EHRs and better warning label strategies. By Theresa Gaffney Adobe Opinion: The Biden administration should not support a WTO petition to strip IP protections from Covid-19 treatments There is no evidence to support claims that IP waivers could expand access to shots, therapeutics, and diagnostics in the developing world. By David Kappos and Andrei Iancu

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser